Sarcomas

The FDA approved the radiopharmaceutical agent technetium Tc 99m tilmanocept injection (Lymphoseek) for accurate and precise lymph node identification in pediatric patients with melanoma, rhabdomyosarcoma, and other types of solid tumors.

The heat shock protein 90 inhibitor pimitespib led to a significant improvement in progression-free survival and prolongation in overall survival compared with placebo in patients with advanced gastrointestinal stromal tumor that is refractory to imatinib, sunitinib, and regorafenib.

John Raymond Zalcberg, discusses the efficacy of intra-patient dose escalation with ripretinib in patients with advanced gastrointestinal stromal tumors, as demonstrated in an analysis of the phase 3 INVICTUS trial.

Selpercatinib demonstrated evidence of preliminary efficacy and safety in pediatric patients with advanced RET-altered solid tumors.

Sylvie Bonvalot, MD, PhD, HDR, discusses the long-term safety of NBTXR3 plus radiotherapy in patients with locally advanced soft tissue sarcoma who were treated in the phase 2/3 Act.In.Sarc trial.

Encouraging initial durability has been observed with afamitresgene autoleucel in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma, according to data from the phase 2 SPEARHEAD-1 trial.

Catequentinib improved disease control and progression-free survival in patients with advanced synovial sarcoma compared with dacarbazine.

Intra-patient dose escalation of ripretinib to 150 mg twice a day following disease progression extended progression-free survival for patients with advanced gastrointestinal stromal tumor after receiving fourth-line therapy.

The phase 2 ENVASARC trial, which is examining the PD-L1 antibody envafolimab with and without ipilimumab in patients with undifferentiated pleomorphic sarcoma and myxofibrosarcoma, has been recommended by the Independent Data Monitoring Committee to continue as planned.

Innovative strategies are vital for patients diagnosed with rare cancers, who are frequently at a disadvantage compared with those who have more common malignancies, experts say.

The new drug application seeking the approval of a unique formulation of sodium thiosulfate for the prevention of ototoxicity induced by cisplatin chemotherapy in patients aged 1 month to less than 18 years of age with localized, nonmetastatic solid tumors has been resubmitted to the FDA.

Afamitresgene autoleucel was found be efficacious with favorable tolerability in heavily pretreated patients with advanced synovial sarcoma or myxoid/round cell liposarcoma, according to data from phase 2 SPEARHEAD-1 trial.

Dysregulated platelet-derived growth factor receptor signaling is implicated in a number of cancer types and is among the targets of many FDA-approved multikinase inhibitors.

MEK inhibition combined with an anti-IGFR1 agent shrank tumors in pediatric PAX fusion–negative rhabdomyosarcoma.

Early detection and quick intervention of abdominal metastases in patients with osteosarcoma could be a tactic to improve patient outcomes as well as palliative care.

William D. Tap, MD, discusses the effects of the COVID-19 pandemic on the treatment of patients with sarcoma.

Richard Gorlick, MD, discusses the challenges of identifying immunotherapeutic targets in osteosarcomas.

Dr. Riedel and Dr. Van Tine discuss the multidisciplinary management of patients with sarcoma, the clinical impact of the FDA approval of ripretinib in the gastrointestinal stromal tumor paradigm, and other exciting advances in sarcoma.

Intraperitoneal radioimmunotherapy with the anti-B7H3 murine monoclonal antibody 131I-omburtamab was well tolerated with low radiation exposure to normal organs, making it a feasible option to combine with other therapies in patients with desmoplastic small round cell tumor.

The local recurrence rate after surgical excision was similar to the rate of progression with active surveillance in patients with extra-abdominal desmoid tumor fibromatosis, suggesting that observation may be sufficient in some cases.

Richard Gorlick, MD, discusses the potential of antibody-drug conjugates in patients with osteosarcoma.

Selinexor resulted in lower rates and slower worsening of pain in patients with advanced unresectable dedifferentiated liposarcoma vs placebo, and may represent a novel option to provide convenience, improved adherence, and reduced caregiver burden vs existing parenteral therapies.

Reattaching the greater trochanter to the proximal femur endoprosthesis did not show an improvement in Trendelburg gait or reliance on an assistive ambulatory device vs a soft tissue–only abductor repair in patients with bone cancers.

Richard Gorlick, MD, highlights methods for identifying immunotherapeutic targets in osteosarcomas.

Vivek Subbiah, MD, discusses outcomes with selpercatinib in patients with RET fusion–positive cancer.